Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array

Hum Pathol. 2016 Sep:55:72-82. doi: 10.1016/j.humpath.2016.04.015. Epub 2016 May 14.

Abstract

Malignant peritoneal mesotheliomas (MPM) are rare, accounting for approximately 8% of cases of mesothelioma in France. We performed comparative genomic hybridization (CGH) on frozen MPM samples using the Agilent Human Genome CGH 180 K array. Samples were taken from a total of 33 French patients, comprising 20 men and 13 women with a mean (range) age of 58.4 (17-76) years. Asbestos exposure was reported in 8 patients (24.2%). Median (range) overall survival (OS) was 39 (0-119) months. CGH analysis demonstrated the presence of chromosomal instability in patients with MPM, with a genomic pattern that was similar to that described for pleural mesothelioma, including the loss of chromosomal regions 3p21, 9p21, and 22q12. In addition, novel genomic copy number alterations were identified, including the 15q26.2 region and the 8p11.22 region. Median OS was associated with a low peritoneal cancer index (P=.011), epithelioid subtype (P=.038), and a low number of genomic aberrations (P=.015), all of which constitute good prognostic factors for MPM. Our results provide new insights into the genetic and genomic background of MPM. Although pleural and peritoneal mesotheliomas have different risk factors, different therapeutics, and different prognosis; these data provide support to combine pleural and peritoneal mesothelioma in same clinical assays.

Keywords: Asbestos; Comparative genomic hybridization; Copy number alterations; Malignant peritoneal mesothelioma; VEGF-B.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Asbestos / adverse effects
  • Biomarkers, Tumor / genetics*
  • Chromosomal Instability
  • Comparative Genomic Hybridization*
  • DNA Copy Number Variations*
  • Female
  • France
  • Gene Amplification*
  • Gene Dosage*
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry
  • Inhalation Exposure / adverse effects
  • Kaplan-Meier Estimate
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Male
  • Mesothelioma / genetics*
  • Mesothelioma / mortality
  • Mesothelioma / pathology
  • Mesothelioma / therapy
  • Mesothelioma, Malignant
  • Middle Aged
  • Peritoneal Neoplasms / genetics*
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / therapy
  • Phenotype
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Risk Factors
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Asbestos